VRC-300 (NIH 03-I-0285) was approved by the NIAID IRB. Through this protocol, the VRC has initiated recruitment of healthy, HIV-negative subjects for a clinical trial of an investigational Ebola vaccine trial. The protocol may also be used in the future to recruit and screen for vaccine studies for infectious diseases other than HIV. The results of these screening studies will be used to determine if the subject meets eligibility requirements for participation in Phase I trials of preventative vaccines. Educational materials on vaccines are reviewed with and provided to subjects before enrollment into a study. Some of these vaccine studies will be part of the VRC Biodefense agenda.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI005047-01
Application #
6822473
Study Section
(VRC)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2003
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Sullivan, Nancy J; Martin, Julie E; Graham, Barney S et al. (2009) Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7:393-400
Martin, Julie E; Pierson, Theodore C; Hubka, Sarah et al. (2007) A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196:1732-40
Martin, Julie E; Sullivan, Nancy J; Enama, Mary E et al. (2006) A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13:1267-77